6533b85bfe1ef96bd12bbedf

RESEARCH PRODUCT

Dihydrocucurbitacin B, isolated from Cayaponia tayuya, reduces damage in adjuvant-induced arthritis

José M. EscandellJosé-luis RíosMiguel Cerdá-nicolásMaría-carmen RecioRosa-maría GinerSalvador Máñez

subject

medicine.medical_specialtyCell Survivalmedicine.medical_treatmentAnti-Inflammatory AgentsAdministration OralNitric Oxide Synthase Type IIPainArthritisPlant RootsDinoprostoneCell LineNitric oxidechemistry.chemical_compoundSuperoxidesInternal medicinemedicineAnimalsLymphocytesNitritesPharmacologyDose-Response Relationship DrugPancreatic ElastasebiologyPlant Extractsbusiness.industryMacrophagesElastasemedicine.diseasebiology.organism_classificationArthritis ExperimentalTriterpenesCayaponia tayuyaRatsEnzyme ActivationNitric oxide synthaseCucurbitaceaeEndocrinologyCytokinechemistryCyclooxygenase 2Rats Inbred LewAntirheumatic AgentsToxicitybiology.proteinCytokinesFemaleTumor necrosis factor alphabusinessPhytotherapy

description

23,24-Dihydrocucurbitacin B, from the anti-rheumatic plant Cayaponia tayuya, was tested on arthritis induced by adjuvant to corroborate the anti-inflammatory properties of this plant. Arthritis was induced in Lewis rats; the resulting arthritic rats were then treated with dihydrocucurbitacin B (1 mg/kg orally, daily, 1 week). The effect of dihydrocucurbitacin B on the synthesis, release, and activity of pro-inflammatory enzymes (elastase, cyclooxygenase-2, and nitric oxide synthase-2) as well as its effect on different mediators (tumor necrosis factor-alpha and interleukin-1beta) were determined. Dihydrocucurbitacin B modified the evolution of the clinical symptoms, reducing the swelling and bone and tissue damage along with the development of the disease, modifying the cell infiltration and the expression of both nitric oxide synthase-2 and cyclooxygenase-2. In addition, it decreased the tumor necrosis factor-alpha and interleukin-1beta production in lymphocytes, but did not modify it in macrophages.

yearjournalcountryeditionlanguage
2005-09-28European Journal of Pharmacology
https://doi.org/10.1016/j.ejphar.2005.12.028